Reaction
Application Site Hypersensitivity reporting signals
As of the last recalculation, Application Site Hypersensitivity appears in 1,191 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is RIVASTIGMINE (PRR 62.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Rivastigmine | 64 | 62.7 | 62.9 |
| Rotigotine | 37 | 46.1 | 46.2 |
| Estradiol | 118 | 26.4 | 26.4 |
| Minoxidil | 62 | 25.4 | 25.4 |
| Nicotine | 49 | 22.0 | 22.1 |
| Estradiol Gel 0.1% | 42 | 16.8 | 16.8 |
| Estradiol Transdermal | 42 | 16.8 | 16.8 |
| Buprenorphine | 83 | 16.8 | 16.8 |
| Methylphenidate | 25 | 15.4 | 15.4 |
| Epoprostenol | 11 | 14.8 | 14.8 |
| Crisaborole | 8 | 14.7 | 14.7 |
| Minoxidil Foam 5% (Womens) | 26 | 14.1 | 14.1 |
| Memantine | 8 | 10.3 | 10.3 |
| Memantine Hydrochloride | 8 | 10.3 | 10.3 |
| Nicotine Polacrilex | 14 | 6.5 | 6.5 |
| Tapentadol Hydrochloride | 9 | 4.7 | 4.7 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 5 | 2.8 | 2.8 |
| Adapalene | 4 | 0.4 | 0.4 |